Ebola, the first vaccines available

被引：2

作者：

Martin, Baptiste ^{[1
]}

Volchkov, Viktor ^{[1
]}

Reynard, Olivier ^{[1
]}

机构：

[1] Univ Claude Bernard Lyon 1, Univ Lyon, Equipe Bases Mol Pathogenicite Virale, CNRS,UMR5308,ENS Lyon,CIRI,Inserm,U1111, F-69007 Lyon, France

来源：

M S-MEDECINE SCIENCES | 2020年 / 36卷 / 11期

关键词：

VESICULAR STOMATITIS-VIRUS; PROTECTS NONHUMAN-PRIMATES; MARBURG VIRUS; DOUBLE-BLIND; VECTORED VACCINE; SAFETY; DISEASE; IMMUNOGENICITY; GLYCOPROTEIN; ANTIBODY;

D O I：

10.1051/medsci/2020174

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

In the recent years, Ebola virus has been responsible for several major epidemics. Research efforts have allowed the development and evaluation in the field of several vaccine candidates. At present, two of them are already approved and used in the fight against the virus in the Democratic Republic of Congo. This review aims to describe the different candidates, the clinical trials that have been conducted as well as the first results in the field.

引用

页码：1027 / 1033

页数：7

共 46 条

[1] Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe [J].

Agnandji, S. T. ;

Huttner, A. ;

Zinser, M. E. ;

Njuguna, P. ;

Dahlke, C. ;

Fernandes, J. F. ;

Yerly, S. ;

Dayer, J. -A. ;

Kraehling, V. ;

Kasonta, R. ;

Adegnika, A. A. ;

Altfeld, M. ;

Auderset, F. ;

Bache, E. B. ;

Biedenkopf, N. ;

Borregaard, S. ;

Brosnahan, J. S. ;

Burrow, R. ;

Combescure, C. ;

Desmeules, J. ;

Eickmann, M. ;

Fehling, S. K. ;

Finckh, A. ;

Goncalves, A. R. ;

Grobusch, M. P. ;

Hooper, J. ;

Jambrecina, A. ;

Kabwende, A. L. ;

Kaya, G. ;

Kimani, D. ;

Lell, B. ;

Lemaitre, B. ;

Lohse, A. W. ;

Massinga-Loembe, M. ;

Matthey, A. ;

Mordmueller, B. ;

Nolting, A. ;

Ogwang, C. ;

Ramharter, M. ;

Schmidt-Chanasit, J. ;

Schmiedel, S. ;

Silvera, P. ;

Stahl, F. R. ;

Staines, H. M. ;

Strecker, T. ;

Stubbe, H. C. ;

Tsofa, B. ;

Zaki, S. ;

Fast, P. ;

Moorthy, V. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (17) :1647-1660

[2]

[Anonymous], 2015, AM J PHARM BENEFITS, V7, pe141

[3]

[Anonymous], 2018, LANCET

[4] Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania [J].

Anywaine, Zacchaeus ;

Whitworth, Hilary ;

Kaleebu, Pontiano ;

Praygod, George ;

Shukarev, Georgi ;

Manno, Daniela ;

Kapiga, Saidi ;

Grosskurth, Heiner ;

Kalluvya, Samuel ;

Bockstal, Viki ;

Anumendem, Dickson ;

Luhn, Kerstin ;

Robinson, Cynthia ;

Douoguih, Macaya ;

Watson-Jones, Deborah .

JOURNAL OF INFECTIOUS DISEASES, 2019, 220 (01) :46-56

[5] Safety, immunogenicity and risk-benefit analysis of rVSV-ΔG-ZEBOV-GP (V920) Ebola vaccine in Phase I-III clinical trials across regions [J].

Bache, Bache Emmanuel ;

Grobusch, Martin P. ;

Agnandji, Selidji Todagbe .

FUTURE MICROBIOLOGY, 2020, 15 (02) :85-106

[6] Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice [J].

Bengtsson, Karin Lovgren ;

Song, Haifeng ;

Stertman, Linda ;

Liu, Ye ;

Flyer, David C. ;

Massare, Michael J. ;

Xu, Ren-Huan ;

Zhou, Bin ;

Lu, Hanxin ;

Kwilas, Steve A. ;

Hahn, Timothy J. ;

Kpamegan, Eloi ;

Hooper, Jay ;

Carrion, Ricardo, Jr. ;

Glenn, Gregory ;

Smith, Gale .

VACCINE, 2016, 34 (16) :1927-1935

[7] Inactivated or Live-Attenuated Bivalent Vaccines That Confer Protection against Rabies and Ebola Viruses [J].

Blaney, Joseph E. ;

Wirblich, Christoph ;

Papaneri, Amy B. ;

Johnson, Reed F. ;

Myers, Carey J. ;

Juelich, Terry L. ;

Holbrook, Michael R. ;

Freiberg, Alexander N. ;

Bernbaum, John G. ;

Jahrling, Peter B. ;

Paragas, Jason ;

Schnell, Matthias J. .

JOURNAL OF VIROLOGY, 2011, 85 (20) :10605-10616

[8] Chimeric human parainfluenza virus bearing the Ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against Ebola virus challenge [J].

Bukreyev, Alexander ;

Marzi, Andrea ;

Feldmann, Friederike ;

Zhang, Liqun ;

Yang, Lijuan ;

Ward, Jerrold M. ;

Dorward, David W. ;

Pickles, Raymond J. ;

Murphy, Brian R. ;

Feldmann, Heinz ;

Collins, Peter L. .

VIROLOGY, 2009, 383 (02) :348-361

[9] Safety and immunogenicity of a highly attenuated rVSVN4CT1-EBOVGP1 Ebola virus vaccine: a randomised, double-blind, placebo-controlled, phase 1 clinical trial [J].

Clarke, David K. ;

Xu, Rong ;

Matassov, Demetrius ;

Latham, Theresa E. ;

Ota-Setlik, Ayuko ;

Gerardi, Cheryl S. ;

Luckay, Amara ;

Witko, Susan E. ;

Hermida, Luz ;

Higgins, Terry ;

Tremblay, Marc ;

Sciotto-Brown, Susan ;

Chen, Tracy ;

Egan, Michael A. ;

Rusnak, Janice M. ;

Ward, Lucy A. ;

Eldridge, John H. .

LANCET INFECTIOUS DISEASES, 2020, 20 (04) :455-466

[10] Postexposure Prophylaxis With rVSV-ZEBOV Following Exposure to a Patient With Ebola Virus Disease Relapse in the United Kingdom: An Operational, Safety, and Immunogenicity Report [J].

Davis, Chris ;

Tipton, Tom ;

Sabir, Suleman ;

Aitken, Celia ;

Bennett, Susan ;

Becker, Stephan ;

Evans, Tom ;

Fehling, Sarah Katharina ;

Gunson, Rory ;

Hall, Yper ;

Jackson, Celia ;

Johanssen, Ingolfur ;

Kieny, Marie Paule ;

Mcmenamin, Jim ;

Spence, Elizabeth ;

Strecker, Thomas ;

Sykes, Catie ;

Templeton, Kate ;

Thorburn, Fiona ;

Peters, Erica ;

Restrepo, Ana Maria Henao ;

White, Beth ;

Zambon, Maria ;

Carroll, Miles W. ;

Thomson, Emma C. .

CLINICAL INFECTIOUS DISEASES, 2020, 71 (11) :2872-2879

← 1 2 3 4 5 →